Tolera Therapeutics Inc., a pharma startup developing a novel T-cell targeted therapeutic platform, announced Tuesday that it has appointed Ashleigh Palmer as president, CEO and a member of its board.
The pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today’s cholesterol-lowering statin drugs.
The Ann Arbor pharma startup Lycera Corp. Tuesday announced a collaboration with pharma giant Merck to discover, developand commercialize small-molecule therapies directed at novel targets to treat a broad range of immune system disorders.
Tetra Discovery Partners LLC, a developer of new treatments for major neurological conditions based on PDE4 modulation in the brain, announced it has been awarded a five-year cooperative agreement by the National Institutes of Health.
Ann Arbor-based Adeona Pharmaceuticals Inc. said Thursday that it had an agreement for the sale of 1,688,782 shares of its common stock at $2.0725 per share to a new institutional investor in a registered direct offering for $3.5 million in gross proceeds
The Ann Arbor pharma startup Adeona Pharmaceuticals Inc. (Amex: AEN) said Friday that it had executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds